Back to results
US 9,308,204 B2Granted
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
AssigneePfizer Inc.
InventorVincent Mascitti
Life of this patent
Estimating the term…
Abstract
Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
Claims4
A pharmaceutical composition comprising:
- (i) (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol;
- (ii) a pharmaceutically acceptable excipient, diluent, or carrier;
- and (iii) sitagliptin.
A pharmaceutical composition comprising:
- (i) (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol;
- (ii) a pharmaceutically acceptable excipient, diluent, or carrier;
- and (iii) metformin.
Dependencies are inferred from the claim text.